Primary Site >> Esophagus Cancer
Gene >> EGFR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: [Expression of the epidermal growth factor receptor in esophageal cancer]. PMID: 2681876 |
Ref: Expression of human epidermal growth factor and its receptor in esophageal cancer. PMID: 2193179 Ref: EGF and TGF-alpha, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. PMID: 2298497 |
Ref: Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. PMID: 2049734 |
Ref: [Studies on biological characteristics of undifferentiated carcinoma of the esophagus]. PMID: 1373428 Ref: [New prognostic factors in patients with esophageal squamous carcinoma]. PMID: 1530906 |
Ref: Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. PMID: 8098013 Ref: Intratumoral heterogeneity of DNA ploidy and regional differences in epidermal growth factor and epidermal growth factor receptor of esophageal carcinoma. PMID: 8128479 Ref: Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. PMID: 8280379 Ref: erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines. PMID: 8286103 Ref: Growth-regulatory mechanism of two human esophageal-cancer cell lines in protein-free conditions. PMID: 8375919 Ref: Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. PMID: 8490817 Ref: Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. PMID: 8491760 |
Ref: Serum levels of c-erbB-2 protein in digestive diseases. PMID: 7528080 Ref: Esophageal cancer. PMID: 7533069 Ref: [Alterations of oncogenes in human fetal esophageal epithelium induced by N-methylbenzylnitrosamine (NMBzA)]. PMID: 7720492 Ref: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. PMID: 8039107 |
Ref: Epidermal growth-factor receptors and erbb2 protein expression in esophageal cancer and normal mucosa. PMID: 21597745 |
Ref: Basaloid-squamous carcinoma of the esophagus. A clinicopathologic, DNA ploidy, and immunohistochemical study of seven cases. PMID: 8604812 Ref: [Prognostic factors for esophageal cancer--from the viewpoint of molecular biology]. PMID: 8687232 Ref: [Genetic events during development of esophageal squamous cell carcinoma]. PMID: 8920674 |
Ref: Effect of suramin on human esophageal cancer cells in vitro and in vivo. PMID: 9282976 Ref: Gene amplification of int-2 and erbB in human esophageal cancer: relationship to clinicopathological variables. PMID: 9316622 |
Ref: Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. PMID: 10071802 |
Ref: Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. PMID: 10037277 Ref: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. PMID: 10512940 |
Ref: What's new in imaging? New magnetic resonance imaging of esophageal cancer using an endoluminal surface coil and antibody-coated magnetite particles. PMID: 10693240 Ref: Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. PMID: 10763823 Ref: Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. PMID: 10908564 |
Ref: Tumor marker expression is predictive of survival in patients with esophageal cancer. PMID: 11565671 |
Ref: Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. PMID: 12000603 Ref: [Molecular alterations in esophageal cancer]. PMID: 12094695 Ref: Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1. PMID: 12162406 |
Ref: Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. PMID: 15007244 Ref: Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. PMID: 15161032 Ref: Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. PMID: 15520175 |
Ref: [Expressions of epithelial growth factor receptor and E-cadherin in esophageal carcinoma and their correlation]. PMID: 15694044 Ref: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. PMID: 15737843 Ref: Novel targeted therapies in the treatment of gastric and esophageal cancer. PMID: 15980157 Ref: ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. PMID: 16023108 Ref: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. PMID: 16140980 Ref: Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. PMID: 16425431 |
Ref: Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. PMID: 16217753 Ref: Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. PMID: 16357520 Ref: Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. PMID: 16488438 Ref: Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. PMID: 16508686 Ref: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. PMID: 16575012 Ref: Novel targets in gastric and esophageal cancer. PMID: 16829119 Ref: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. PMID: 16857803 Ref: Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. PMID: 17079462 |
Ref: Identification of EGFR mutations in esophageal cancer. PMID: 17142003 Ref: Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. PMID: 17143494 Ref: The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. PMID: 17342332 Ref: Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. PMID: 17496429 Ref: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. PMID: 17609492 Ref: Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. PMID: 17912028 Ref: The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. PMID: 17974918 Ref: Epidermal growth factor receptor-directed therapy in esophageal cancer. PMID: 18477853 |
Ref: [News in digestive oncology]. PMID: 18230577 Ref: Epidermal growth factor-induced esophageal cancer cell proliferation requires transactivation of beta-adrenoceptors. PMID: 18369180 Ref: Predictive factors of the response to chemoradiotherapy in esophageal cancer. PMID: 18555630 Ref: Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer. PMID: 18773861 Ref: Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. PMID: 18845990 Ref: Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas. PMID: 19133013 |
Ref: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. PMID: 19136271 Ref: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. PMID: 19236713 Ref: Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. PMID: 19302210 Ref: Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. PMID: 19424628 Ref: Emerging drugs for esophageal cancer. PMID: 19453287 Ref: Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. PMID: 19636422 Ref: Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximab. PMID: 19744737 |
Ref: Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. PMID: 19823871 Ref: A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. PMID: 19956829 Ref: Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. PMID: 20039326 Ref: Chromosomal imbalances are uncommon in chagasic megaesophagus. PMID: 20163722 Ref: Specificity protein 1 regulates fascin expression in esophageal squamous cell carcinoma as the result of the epidermal growth factor/extracellular signal-regulated kinase signaling pathway activation. PMID: 20502940 Ref: Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. PMID: 20513670 Ref: Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array--comparative genomic hybridization. PMID: 20620594 Ref: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. PMID: 20679611 |
Ref: Aberrant expression of epidermal growth factor receptor and its interaction with protein kinase C delta in inflammation associated neoplastic transformation of human esophageal epithelium in high risk populations. PMID: 21155880 Ref: Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. PMID: 21207425 Ref: Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. PMID: 21298351 Ref: A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. PMID: 21425140 Ref: Ultra-small particles of iron oxide as peroxidase for immunohistochemical detection. PMID: 21454943 Ref: The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. PMID: 21572404 Ref: Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. PMID: 21615826 Ref: An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. PMID: 21936950 Ref: Trimodal therapy in squamous cell carcinoma of the esophagus. PMID: 22024422 |
Ref: RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. PMID: 22265016 Ref: Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. PMID: 22293713 Ref: Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. PMID: 22311160 Ref: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. PMID: 22407299 Ref: Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. PMID: 22450065 Ref: Current developments in the management of locally advanced esophageal cancer. PMID: 22544559 Ref: Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. PMID: 22555809 Ref: Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. PMID: 22645717 Ref: pERK activation in esophageal carcinomas: clinicopathological associations. PMID: 22658382 Ref: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. PMID: 22751462 Ref: High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PMID: 22870241 Ref: Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. PMID: 22935382 Ref: Targetting esophageal and gastric cancers with monoclonal antibodies. PMID: 22978338 Ref: [Update on Barrett esophagus and Barrett carcinoma]. PMID: 23011020 Ref: Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study. PMID: 23052161 Ref: Adenocarcinoma of the GEJ: gastric or oesophageal cancer? PMID: 23129369 |
Ref: Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. PMID: 22458639 Ref: The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. PMID: 22585382 Ref: Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. PMID: 23255886 Ref: Synthesis and characterization of anti-EGFR fluorescent nanoparticles for optical molecular imaging. PMID: 23273065 Ref: Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. PMID: 23591158 Ref: Esophageal carcinoma: are modern targeted therapies shaking the rock? PMID: 23680713 Ref: Emerging tyrosine kinase inhibitors for esophageal cancer. PMID: 23725567 Ref: Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma. PMID: 23749888 Ref: Epidermal growth factor receptor: an important target in esophageal cancer. PMID: 23855932 Ref: Distinct genetic aberrations in oesophageal adeno and squamous carcinoma. PMID: 24102414 Ref: Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer. PMID: 24122977 Ref: Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. PMID: 24235844 Ref: Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PMID: 24312376 |
Ref: EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer. PMID: 23377570 Ref: Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions. PMID: 24021598 Ref: EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. PMID: 24510732 Ref: Targeted therapies in metastatic esophageal cancer: advances over the past decade. PMID: 24582516 Ref: An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer. PMID: 24664246 Ref: New directions in perioperative management of locally advanced esophagogastric cancer. PMID: 24857100 Ref: Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma. PMID: 24993015 Ref: Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. PMID: 24999713 Ref: [Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers]. PMID: 25030589 Ref: Expression and significance of molecular biomarkers in esophageal carcinoma in different nationalities patients in Xinjiang. PMID: 25078598 Ref: ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. PMID: 25091467 Ref: Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study. PMID: 25195993 Ref: Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression. PMID: 25242085 Ref: The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws? PMID: 25256600 Ref: Aquaporin-8 mediates human esophageal cancer Eca-109 cell migration via the EGFR-Erk1/2 pathway. PMID: 25550802 |
Ref: A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis. PMID: 25351873 Ref: Gefitinib extends survival in some esophageal cancers. PMID: 25583816 Ref: Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. PMID: 25694417 Ref: The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. PMID: 25714027 Ref: The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. PMID: 25739674 Ref: Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair. PMID: 25750543 Ref: Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells. PMID: 25788032 Ref: Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. PMID: 25826681 Ref: The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang. PMID: 26099724 Ref: High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. PMID: 26124180 Ref: Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). PMID: 26350593 Ref: Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. PMID: 26392415 Ref: MTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous Reports. PMID: 26456456 Ref: In vivo multiplexed molecular imaging of esophageal cancer via spectral endoscopy of topically applied SERS nanoparticles. PMID: 26504623 Ref: Expression and prognostic influence of NF-kappaB and EGFR in esophageal cancer. PMID: 26681028 Ref: Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma. PMID: 26788193 Ref: Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). PMID: 26885448 Ref: [Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer]. PMID: 27337801 |
Ref: The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. PMID: 26459251 Ref: Subcellular localization of EGFR in esophageal carcinoma cell lines. PMID: 26582583 Ref: High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. PMID: 26766917 Ref: Effect of recombinant human endostatin onradiotherapy for esophagus cancer. PMID: 26851794 Ref: DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma. PMID: 26856390 Ref: Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. PMID: 26873401 Ref: Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells. PMID: 26893678 Ref: Targeted therapy in esophageal cancer. PMID: 26895097 Ref: Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression. PMID: 27420968 Ref: Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer. PMID: 27499966 Ref: [Effects and its mechanism of Nimotuzumab on radiosensitivity of esophageal carcinoma ECA-109 and TE-13 cell lines]. PMID: 27784455 Ref: Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers. PMID: 28078044 |
Ref: Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. PMID: 26986978 Ref: Up-Regulation of MicroRNA-133a Inhibits the MEK/ERK Signaling Pathway to Promote Cell Apoptosis and Enhance Radio-Sensitivity by Targeting EGFR in Esophageal Cancer In Vivo and In Vitro. PMID: 27933650 Ref: The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKalpha/mTOR pathway in vitro and in vivo. PMID: 28052030 Ref: The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. PMID: 28120720 Ref: Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. PMID: 28286209 Ref: Single molecule force spectroscopy for in-situ probing oridonin inhibited ROS-mediated EGF-EGFR interactions in living KYSE-150 cells. PMID: 28411855 Ref: EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran. PMID: 28412829 Ref: Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines. PMID: 28415738 Ref: A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. PMID: 28498434 Ref: Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. PMID: 28537764 Ref: Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. PMID: 28687830 Ref: Targeted next-generation sequencing supports epidermoid metaplasia of the esophagus as a precursor to esophageal squamous neoplasia. PMID: 28731047 Ref: Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma. PMID: 28811223 Ref: Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification. PMID: 28881608 Ref: GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. PMID: 29019267 Ref: [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors]. PMID: 29239193 |
Ref: The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. PMID: 28183250 Ref: Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation. PMID: 29059172 Ref: HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. PMID: 29223420 Ref: Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo. PMID: 29290767 Ref: Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. PMID: 29455652 Ref: Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment. PMID: 29516969 Ref: Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation. PMID: 29592879 Ref: Is there a future for EGFR targeted agents in esophageal cancer? PMID: 29668836 Ref: Quercetin-3-methyl ether inhibits esophageal carcinogenesis by targeting the AKT/mTOR/p70S6K and MAPK pathways. PMID: 30035335 Ref: WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma. PMID: 30202417 Ref: What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies? PMID: 30231398 Ref: Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. PMID: 30388386 |